[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,637,601
  • Shares Outstanding, K 116,106
  • Annual Sales, $ 0 K
  • Annual Income, $ -359,640 K
  • EBIT $ -502 M
  • EBITDA $ -511 M
  • 60-Month Beta 0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.31

Options Overview Details

View History
  • Implied Volatility 61.59% (+2.44%)
  • Historical Volatility 54.46%
  • IV Percentile 5%
  • IV Rank 5.58%
  • IV High 170.22% on 08/12/25
  • IV Low 55.17% on 04/30/26
  • Expected Move (DTE 5) 1.70 (5.43%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 5,889
  • Volume Avg (30-Day) 9,406
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 193,743
  • Open Int (30-Day) 173,187
  • Expected Range 29.63 to 33.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.17
  • Number of Estimates 10
  • High Estimate $-0.81
  • Low Estimate $-1.38
  • Prior Year $-0.58
  • Growth Rate Est. (year over year) -101.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.82 +8.71%
on 04/30/26
36.79 -14.84%
on 04/15/26
-2.34 (-6.95%)
since 04/08/26
3-Month
27.17 +15.33%
on 02/11/26
37.50 -16.45%
on 03/13/26
+2.89 (+10.16%)
since 02/06/26
52-Week
22.96 +36.46%
on 09/17/25
43.15 -27.39%
on 11/12/25
+3.48 (+12.50%)
since 05/08/25

Most Recent Stories

More News
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735

VKTX : 31.33 (-0.79%)
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside

VKTX : 31.33 (-0.79%)
NVO : 46.07 (+0.59%)
LLY : 948.45 (-2.72%)
Dozens of Experts Built This Simple Stock Screener for Traders & Investors. It Was Me.

Find out the major metrics that really matter when it comes to finding quality stocks, no matter how you prefer to play the market.

GRND : 15.09 (+9.27%)
QQQ : 711.23 (+2.34%)
MSFT : 415.12 (-1.34%)
VKTX : 31.33 (-0.79%)
AVGO : 430.00 (+4.23%)
KO : 78.42 (-0.01%)
IWB : 402.33 (+0.73%)
AMD : 455.19 (+11.44%)
SPY : 737.62 (+0.83%)
MCD : 275.75 (-2.80%)
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

VKTX : 31.33 (-0.79%)
Viking Therapeutics Reports Another Quarter of Spending Other People's Money on Promise

Barchart Research What to Expect from VKTX Earnings VKTX Generated April 28, 2026 Current Price $32.39 EPS Estimate $$-0.95 Consensus Rating Strong Buy Average Move 9.63% Viking Therapeutics Reports Another...

VKTX : 31.33 (-0.79%)
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Conference Call Scheduled for   Wednesday, April 29 at 4:30 p.m. Eastern Time  

VKTX : 31.33 (-0.79%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 31.33 (-0.79%)
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes

VKTX : 31.33 (-0.79%)
3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

VKTX : 31.33 (-0.79%)
LLY : 948.45 (-2.72%)
GPCR : 39.10 (-0.13%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 31.33 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 32.54
2nd Resistance Point 32.22
1st Resistance Point 31.77
Last Price 31.33
1st Support Level 31.01
2nd Support Level 30.69
3rd Support Level 30.25

See More

52-Week High 43.15
Fibonacci 61.8% 35.44
Fibonacci 50% 33.05
Last Price 31.33
Fibonacci 38.2% 30.67
52-Week Low 22.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.